An effective method making vaccines without the use of inactivated virus (w/video)

(Nanowerk News) The best vaccines available are based on "inactivated virus", i.e. live viruses chemically or physically treated to eliminate their infectivity. This method involves a number of important biological hazards, that require relevant safety measures. Therefore, there are many attempts to replace this kind of vaccines with lower risk options, like "subunit vaccines", which only present some viral proteins, specifically those that trigger the immune response. Thus, it would not be necessary either to work with live and/or inactivated viruses, representing a great advantage when dealing with the most dangerous virus.
The main problem is that subunit vaccines are generally less immunogenic, which means that provide a lesser degree of protection. This is usually compensated for by adding other compounds -adjuvants- that boost the immune response, but may cause adverse effects. An alternative to the usual adjuvants is the inclusion of antigens (proteins that activate the immune response) directly in particulate matter, that is: integrate the proteins into a microparticle.
Biotechnological Tools Based on Viruses
Proven results
The results obtained in this joint research, under the supervision of Prof. José M. Martínez-Costas (CiQUS) and Dr. Javier Ortego (CISA), have demonstrated the effectiveness of a low toxicity based subunit vaccine on the use of particulate biomaterial, whose production is cheap and safe. As a result of this work, published in the journal Antiviral Research ("VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice"), a particulate vaccine against bluetongue virus, which causes considerable losses in sheep, was obtained.
Starting from the technology developed and patented, CiQUS researchers expressed inside insect cells microspheres incorporating some virus proteins -the antigen-, and which are very easily purified to obtain the vaccine. Its effectiveness was verified by immunizing mice with only three proteins of bluetongue virus, incorporated in those microspheres. The vaccine fully protected them against the infection with the same serotype of virus, and partly protected them against a different serotype, generating a protective immune response (so-called effective immunization) without the addition of adjuvants. On the other hand, no mice that had been vaccinated only with the viral proteins survived.
The main advantage of this vaccine technology is its relatively low cost compared to other types of subunit vaccines. It would reduce the need for costly biosafety facilities for the production of vaccines, the microspheres are extremely stable, their production and purification is cheap and they are easy to handle and store. This technology could be applied as well in the search for vaccines against viruses that cause very serious diseases in humans, whose danger not only hinders the investigation, but also discourages the use of inactivated vaccines.
Source: Universidade de Santiago de Compostela
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: